GlassScriptPhysician profile
Robert F Brown
NPI 1134162209
$4,676.34
in general payments reported to CMS, 2019-2025
35 companies · $32.10 in 2025
The $32.10 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,740 · 2020: $584 · 2021: $2,221 · 2022: $35.91 · 2023: $47.07 · 2024: $16.59 · 2025: $32.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $573.35 | 2019-2021 | |
| Novo Nordisk INC | $396.36 | 2019-2021 | |
| Abbvie INC. | $381.87 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $333.58 | 2019-2021 | |
| Astellas Pharma US INC | $288.48 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.32 | 2019-2021 | |
| Pfizer INC. | $287.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $265.18 | 2019-2021 | |
| Esperion Therapeutics, INC. | $204.94 | 2020-2021 | |
| Lilly USA, LLC | $178.78 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $160.10 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $130.64 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $129.01 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $120.97 | 2019-2021 | |
| Amarin Pharma, INC. | $112.71 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $101.21 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.35 | 2019-2022 | |
| Radius Health, INC. | $79.66 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $63.40 | 2021 | |
| Allergan, INC. | $59.57 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.61 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.06 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $40.21 | 2021 | |
| Eisai INC. | $40.16 | 2021 | |
| Jazz Pharmaceuticals INC. | $38.14 | 2021 | |
| Avanir Pharmaceuticals, INC. | $36.55 | 2019 | |
| Sunovion Pharmaceuticals INC. | $31.51 | 2021 | |
| Abbott Laboratories | $23.92 | 2023 | Mitraclip |
| Ironwood Pharmaceuticals, INC | $23.68 | 2021 | |
| Glaxosmithkline, LLC. | $22.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.66 | 2021 | |
| Biogen, INC. | $15.37 | 2021 | |
| Optinose US, INC. | $12.74 | 2021 | |
| Almatica Pharma LLC | $12.31 | 2021 | |
| Sanofi Pasteur INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.